Mabpharm Limited

HKEX:2181.HK

0.295 (HKD) • At close November 14, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) HKD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q22017 Q12016 Q4
Revenue 54.24254.24221.57121.57122.0122.0113.53613.53614.42414.4240.8180.81840.62340.62300005.2685.2681.771.776.886.885.0845.0840000
Cost of Revenue 7.0647.0642.8632.8633.0993.0992.1612.1615.5275.5270.0040.0048.3848.3840000000000000000
Gross Profit 47.17847.17818.70818.70818.91118.91111.37511.3758.8978.8970.8140.81432.23932.23900005.2685.2681.771.776.886.885.0845.0840000
Gross Profit Ratio 0.870.870.8670.8670.8590.8590.840.840.6170.6170.9950.9950.7940.7940000111111110000
Reseach & Development Expenses 28.14728.14731.84231.84229.76429.76434.95834.95838.99538.99550.05950.05981.72881.72829.79529.79530.41430.41437.74337.74329.35229.35231.33131.33113.16113.16122.2465.4085.4085.408
General & Administrative Expenses 30.32630.32628.75328.75323.57723.57721.36321.36323.91623.91623.43923.43921.87821.87817.52717.52715.37115.37117.53317.53313.93313.93313.613.65.9935.9938.5911.2171.2171.217
Selling & Marketing Expenses 34.834.810.9410.9413.52313.5236.4756.4757.6327.6324.7124.7120000000.0030.0030.0090.0091.1141.1140.3590.3590000
SG&A 65.50465.50439.58739.58737.41937.41927.89627.89631.54831.54828.1528.1521.87821.87817.52717.52715.37115.37117.53517.53513.94113.94114.71314.7136.3516.3518.5911.2171.2171.217
Other Expenses 00000000000000000000-104.876-104.876-104.8760-61.646-61.646-61.646-13.559-13.559-13.559
Operating Expenses 93.6593.6571.42970.91266.67266.67256.40756.40765.87165.87173.99373.993104.707104.70765.20665.20629.86929.86948.748.757.71757.71760.38960.38925.69725.697-30.809-6.934-6.934-6.934
Operating Income -46.472-46.472-52.721-52.721-48.272-48.272-51.479-51.479-61.647-61.647-77.395-77.395-71.367-71.367-47.322-47.322-45.785-45.785-52.074-52.074-41.523-41.523-42.667-42.667-17.179-17.179-30.809-6.934-6.934-6.934
Operating Income Ratio -0.857-0.857-2.444-2.444-2.193-2.193-3.803-3.803-4.274-4.274-94.614-94.614-1.757-1.7570000-9.886-9.886-23.466-23.466-6.202-6.202-3.379-3.3790000
Total Other Income Expenses Net -2.313-2.313-1.958-1.958-1.728-1.7284.4744.4743.2423.2424.1034.103-1.214-1.214-17.9-17.918.69118.6916.5876.587-16.318-16.318-12.077-15.58-7.125-7.125-7.339-4.993-4.993-4.993
Income Before Tax -48.785-48.785-54.679-54.679-50-50-47.005-47.005-58.405-58.405-73.292-73.292-72.581-72.581-65.222-65.222-27.094-27.094-43.424-43.424-57.841-57.841-54.744-54.744-21.553-21.553-38.148-11.927-11.927-11.927
Income Before Tax Ratio -0.899-0.899-2.535-2.535-2.272-2.272-3.473-3.473-4.049-4.049-89.598-89.598-1.787-1.7870000-8.244-8.244-32.687-32.687-7.957-7.957-4.239-4.2390000
Income Tax Expense 0000-00-000000000000001.9241.9241.4171.417-0.709-0.709-0.7090.8320.8320.832
Net Income -48.785-48.785-54.679-54.679-50-50-47.005-47.005-58.405-58.405-73.292-73.292-72.581-72.581-65.222-65.222-27.094-27.094-43.424-43.424-57.841-57.841-48.409-48.409-14.033-14.033-37.44-12.759-12.759-12.759
Net Income Ratio -0.899-0.899-2.535-2.535-2.272-2.272-3.473-3.473-4.049-4.049-89.598-89.598-1.787-1.7870000-8.244-8.244-32.687-32.687-7.037-7.037-2.76-2.760000
EPS -0.012-0.012-0.015-0.015-0.012-0.012-0.011-0.011-0.015-0.015-0.018-0.018-0.02-0.02-0.016-0.016-0.007-0.007-0.011-0.011-0.017-0.017-0.018-0.018-0.01-0.01-0.009-0.003-0.003-0.003
EPS Diluted -0.012-0.012-0.013-0.013-0.012-0.012-0.011-0.011-0.014-0.014-0.018-0.018-0.018-0.018-0.016-0.016-0.007-0.007-0.011-0.011-0.017-0.017-0.016-0.016-0.01-0.01-0.009-0.003-0.003-0.003
EBITDA -33.197-33.197-38.549-38.549-36.515-36.515-40.682-40.682-51.157-51.157-67.067-67.067-64.324-64.324-43.055-43.055-41.912-41.912-48.372-48.372-37.952-37.952-39.04-39.04-14.948-14.948-27.88-4.414-4.414-4.414
EBITDA Ratio -0.612-0.612-1.787-1.787-1.659-1.659-3.006-3.006-3.547-3.547-81.99-81.99-1.583-1.5830000-9.183-9.183-21.448-21.448-5.675-5.675-2.94-2.940000